Accessibility Menu
ImpediMed logo

ImpediMed(OTC) IPDQF

Market Cap$14.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-99%
5 Year-96%
1 Year-80%
1 Month+21%
$0.00
-25.93%
-0.00Today
ImpediMed last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-03
ImpediMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-25.23%USD 0.012026-08-27
1 month+21.21%USD 0.002026-07-28
3 month-32.52%USD 0.012026-06-01
Year to date-81.82%USD 0.022025-12-23
1 year-80%USD 0.022025-08-29
3 year-96.92%USD 0.132023-08-23
5 year-96.06%USD 0.102021-09-03
Since inception-99.07%USD 0.432008-11-13

ImpediMed Financials at a Glance

Market Cap

$14.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$27.32M

Net Income (TTM)

-A$48.12M

EPS (TTM)

-$0.01

P/E Ratio

-0.51

Dividend

$0.00

Beta (Volatility)

0.31 (Low)

Price

$0.00

Volume

19,916

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.04

Estimated Earnings Date

Feb 25, 2027

IPDQF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImpediMed

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. Its product SOZO, uses bioimpedance spectroscopy technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. The company was founded by Melvyn John Bridges and Lucille Mayse Bridges on September 27, 1999 and is headquartered in Pinkenba, Australia.

Industry

Healthcare Equipment and Supplies

Employees

66

CEO

Erik S. Anderson, CFA

Headquarters

Carlsbad, CA 92008, US

IPDQF Financials

Key Financial Metrics (TTM)

Gross Margin

-81.36%

Operating Margin

-117.21%

Net Income Margin

-170.44%

Return on Equity

-259.31%

Return on Capital

-206.67%

Return on Assets

-71.86%

Earnings Yield

-1.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.66B

Volume

19.92K

Avg. Volume

27.16K

Financials (TTM)

Gross Profit

-A$903.91K

Operating Income

-A$41.34M

EBITDA

-A$32.56M

Operating Cash Flow

-A$34.66M

Capital Expenditure

A$19.95M

Free Cash Flow

-A$14.71M

Cash & ST Invst.

A$15.26M

Total Debt

A$508.29K

ImpediMed Performance Analysis

ImpediMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 7,631,160-0.4%
20242024-06-30AUD 6,762,815-11.4%
20252025-06-30AUD 8,240,45721.8%
20262026-06-30AUD 9,902,10420.2%
ImpediMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-318.5%
Q42025-06-3011.8%
Q22025-12-3111.9%
Q42026-06-30-5.7%
ImpediMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-10.5%
20242024-06-30AUD -0.01-16.9%
20252025-06-30AUD -0.0117.2%
20262026-06-30AUD -0.015.3%
ImpediMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.6%
Q42025-06-30-76.5%
Q22025-12-31N/A
Q42026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$7.09M

+28.0%

Gross Profit

-A$5.37M

-210.6%

Gross Margin

-75.71%

N/A

Market Cap

$14.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$221.97K

N/A

Employees

66

N/A

Net Income

-A$12.61M

-25.2%

EBITDA

-A$7.50M

+30.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$15.26M

-38.0%

Total Debt

A$508.29K

-55.5%

Accounts Receivable

A$4.67M

+112.9%

Inventory

A$2.21M

+190.9%

Long Term Debt

A$212.70K

-73.7%

Short Term Debt

A$295.58K

-11.2%

Return on Assets

-71.86%

N/A

Return on Invested Capital

-60.13%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$10.51M

+4.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLYYFCelyad Oncology S.A.
$0.28+0.00%
CNTMFFluent Corp.
$0.02+3.77%
PYNKFPerimeter Medical Imaging AI, Inc.
$0.21+0.00%
ELXMFNova Eye Medical Limited
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$101.51+0.06%
WYHGWing Yip Food Group
$5.42+0.33%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.61-0.06%
NOKNokia
$10.40+0.04%

Questions About IPDQF

What is the current price of ImpediMed?

ImpediMed is trading at $0.00 per share.

What is the 52-week range for ImpediMed?

Over the past 52 weeks, ImpediMed has traded between $0.00 and $0.04.

How much debt does ImpediMed have?

As of the most recent reporting period, ImpediMed reported total debt of A$11.50M.

How much cash does ImpediMed have on hand?

ImpediMed reported A$10.59M in cash and cash equivalents in its most recent financial results.

What is ImpediMed’s dividend yield?

ImpediMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.